Japer Therapeutics, Inc. Warrants
JSPRW$0.12 -0.01 (-7.93%)
Company News
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Law firm investigating potential securities misconduct for Driven Brands and Jasper Therapeutics, alleging false statements about business performance and operational practices.
Jasper Reports Wider Loss in Fiscal Q2
Jasper Therapeutics reported a net loss of $1.74 per share in Q2 2025, with no revenue generated. The company is focusing exclusively on briquilimab, a monoclonal antibody for mast cell-driven diseases, while implementing significant cost-cutting measures.
